Vimarsana
Biggest News Aggregation in the World

Page 13 - Drug Controller General News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Controller General. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Controller General Today - Breaking & Trending Today

General Anesthesia Drugs Market to Grow at 3.3% CAGR, Next-Gen Innovations Promise Patient-Centric A - Vimarsana News

General Anesthesia Drugs Market to Grow at 3.3% CAGR, Next-Gen Innovations Promise Patient-Centric A

General Anesthesia Drugs MarketThe global general anesthesia drugs market size is likely to jump from US$ 4,978.1 million in 2023 to US$ 6,898.4 million by 2033. This projected expansion is anticipated to result from a sluggish 3.3% CAGR in the demand for general anesthesia drugs over the upcoming decade.The growing...

Rule regulating Ayush ads set to go, but amendments to fill void in limbo for a year - Vimarsana News

Rule regulating Ayush ads set to go, but amendments to fill void in limbo for a year

The Drug Controller General of India (DCGI) has suggested that a rule regulating the advertisement of ayush drugs should only be withdrawn after amend

Sun Pharma Advanced Research : SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB -November 02, 2023 at 02:47 am EDT - Vimarsana News

Sun Pharma Advanced Research : SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB -November 02, 2023 at 02:47 am EDT

FOR IMMEDIATE RELEASE SPARC enters into an exclusive worldwide license agreement for SCD-153 with JHU and IOCB ...

novo nordisk: Novo Nordisk gets approval to carry out clinical trials on weekly insulin - Vimarsana News

novo nordisk: Novo Nordisk gets approval to carry out clinical trials on weekly insulin

Novo Nordisk has received approval from the Drug Controller General of India to conduct phase-III studies for its new weekly insulin injection, IcoSema, in India. IcoSema is a combination of insulin and Semaglutide and is meant to control blood sugar levels in people with type-two diabetes. The proposed weekly insulin shot could be a game changer as it would decrease the discomfort of daily injections and may be as effective as regular insulin.

Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology - Vimarsana News

Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral...